ArticleNature medicine2023
Dynamics and durability of HIV-1 neutralization are determined by viral replication.
Open access · hybridAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.Nature communications · 2026Trial
- Longitudinal antibody profiling after dengue reveals distinct dynamics by antibody specificity over 18 months.Nature communications · 2026Article
- Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332Nature immunology · 2026Article
- The Germline Targeting Vaccine Concept: Overview and Updates from HIV Pre-Clinical and Clinical Trials.Current HIV research · 2026Review
- Nanocarrier-based immunotherapy for viral diseases.International journal of pharmaceutics: X · 2025Review
- Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.Nature immunology · 2025Article
- Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies.The Journal of clinical investigation · 2025Article
- Identification of a broad and potent V3 glycan site bNAb targeting an N332bioRxiv : the preprint server for biology · 2025Article
- Persistent Low Anti-HIV Neutralizing Antibody Titers in HIV/HCV Coinfection Despite HCV Cure: A 5-Year Longitudinal Analysis.Vaccines · 2025Article
- Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines.Cell reports. Medicine · 2024Article
- The Association of HIV-1 Neutralization in Aviremic Children and Adults with Time to ART Initiation and CD4+/CD8+ Ratios.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 20 institutions in 4 countries.
Philipp SchommersInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0003-3375-6800
Dae Sung KimDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-3191-437X
Maike SchlotzInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Christoph KreerInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-9140-9850
Ralf EggelingMethods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-3583-1029
Anna HakeResearch Group Computational Biology, Max Planck Institute for Informatics, Saarbrücken, Germany.
Melanie StecherDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Juyeon ParkDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Caelan E RadfordMolecular and Cellular Biology Graduate Program, University of Washington, and Basic Sciences Division, Fred Hutch Cancer Center, Seattle, WA, USA.
Adam S DingensBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Meryem S ErcanogluInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Henning GruellInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-0725-7138
Stanley OdidikaDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Marten DahlhausDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Lutz GieselmannInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Elvin AhmadovInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Rene Y LawongInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Eva HegerInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Elena KnopsInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0001-7398-3026
Christoph WyenDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Tim KümmerlePraxis am Ebertplatz, Cologne, Germany.
Katja RömerGemeinschaftspraxis Gotenring, Cologne, Germany.
Stefan ScholtenPraxis Hohenstaufenring, Cologne, Germany.
Timo WolfInfectious Diseases Division, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.ORCID 0000-0002-3819-9540
Christoph StephanInfectious Diseases Division, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.ORCID 0000-0003-3777-9006
Isabelle SuárezDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Nagarajan RajuVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Anurag AdhikariDepartment of Infection and Immunology, Kathmandu Research Institute for Biological Sciences, Lalitpur, Nepal.ORCID 0000-0003-3168-0558
Stefan EsserDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Hendrik StreeckGerman Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
Ralf DuerrDepartment of Microbiology, New York University School of Medicine, New York City, NY, USA.ORCID 0000-0001-9569-9237
Aubin J NanfackMedical Diagnostic Center, Yaoundé, Cameroon.
Susan Zolla-PaznerDepartment of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.ORCID 0000-0002-0750-2666
Christof GeldmacherDivision of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.
Otto GeisenbergerDivision of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.
Arne KroidlDivision of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-3569-9176
Wiston WilliamMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Lucas MagangaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Nyanda Elias NtinginyaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Ivelin S GeorgievVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Jörg J VehreschildDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Michael HoelscherDivision of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-7642-1835
Gerd FätkenheuerDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jason J LavinderDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-1267-3408
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Clara LehmannDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-7042-1578
Nico PfeiferMethods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany.
George GeorgiouDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-8823-3073
Florian KleinInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. florian.klein@uk-koeln.de.ORCID 0000-0003-1376-1792
University of Cologne · DEThe University of Texas at Austin · USLMU Klinikum · DENational Institute for Medical Research · TZGoethe University Frankfurt · DEUniversity of Tübingen · DEBeth Israel Deaconess Medical Center · USCentre International De Reference Chantal Biya · CMFred Hutch Cancer Center · USFriedrich-Ebert-Stiftung e.V. · DEHelmholtz Zentrum München · DEHoward Hughes Medical Institute · USIcahn School of Medicine at Mount Sinai · USMax Planck Institute for Informatics · DENew York University · USPraxis für Humangenetik · DEUniversity of Bonn · DEUniversity of Duisburg-Essen · DEUniversity of Washington · USVanderbilt University · US
Funding
Structure and immunogenicity of novel trimeric HIV-1 Env immunogensR01AI145655 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KONG, XIANGPENG · 2019 to 2023
$4.7MNeutralization Fingerprinting Analysis of Polyclonal Antibody Responses against HIV-1R01AI131722 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GEORGIEV, IVELIN · 2017 to 2021
$4.5MComplete mapping of immune selection from antibodies to HIVR01AI140891 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2019 to 2024
$2.4MNIAID NIH HHS R01 AI131722NIAID NIH HHS R01 AI140891NIAID NIH HHS R01 AI145655
Abstract
Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers-persons with HIV-1 who naturally develop broad and potent nAbs-can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens. To address this, we assessed HIV-1-neutralizing immunoglobulin G (IgG) from 2,354 persons with HIV-1 on or off antiretroviral therapy (ART). Infection with non-clade B viruses, CD4
Indexed as
AIDS VaccinesHIV-1HIV InfectionsAntibodies, NeutralizingHIV AntibodiesHumansVirus ReplicationAIDS VaccinesAntibodies, NeutralizingHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.